We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies. Close

AIPPI 2021: Covid-19 bottlenecks

Intellectual Property Magazine

AIPPI 2021: Covid-19 bottlenecks

TheInternational Federation of Pharmaceutical Manufacturers & Associations’Komal Kalha says barriers to the Covid-19 vaccine are dose sharing, tradebarriers and country readiness, not IP

The proposed Trade-Related Aspects of IntellectualProperty Rights (TRIPs) Covid-19 patent waiver could be “a legal nightmare forthe entire legal community... and changing the law is not easy, even if youneed to change it for emergency proposals” so said the International Federationof Pharmaceutical Manufacturers & Associations’ (IFPMA) Komal Kalha, addingthat a waiver could have “a lot of jurisdictional and legal issue concerns”.

The rest of this document is only available to i-law.com online subscribers.

If you are already a subscriber, please enter your details below to log in.

Enter your email address to log in as a user on your corporate account.
Remember me on this computer

Not yet an i-law subscriber?


Request a trial Find out more